FDA provides fast track designation to nipocalimab for systemic lupus erythematosus
Johnson & Johnson’s nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).This article was originally published on MedicalXpress.com
